Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:706-707 (1 October), doi:10.1136/bmj.331.7519.706
Desirable, achievable, but not easy
| The first 150 words of the full text of this article appear below. |
The steady increase of drug resistant malaria across Africa is a crisis for which there are achievable solutions, but no easy ones. The scale of the problem is not in doubt. In Africa malaria remains one of the commonest causes of death and serious morbidity, especially for children and pregnant women.1 Despite a decision in principle by many countries in Africa to use artemisinin based combination therapies (ACTs), most cases of malaria are still treated with monotherapy and in many areas most of these treatments will fail.2 3
Drug combinations, rather than monotherapy, are now seen to be the best solution for treating malaria, and artemisinin based drug combinations are highly effective, with cure rates similar to that of chloroquine 30 years ago. They seem to be a good long term choice for most African countries, being safe and well tolerated (with the caveat that their safety in early pregnancy
Grace Malenga, director
Malaria Alert Centre, Bantyre, Malawi
Ayo Palmer, director
Centre for Innovation Against Malaria, Banjul, The Gambia
Sarah Staedke, adjunct assistant professor
Makerere University-UCSF Malaria Research Collaboration, PO Box 7475, Kampala, Uganda
Walter Kazadi, policy adviser, West African Network for Monitoring Antimalarial Treatment II
Malaria Consortium, Accra, Ghana
Theonest Mutabingwa, chairman, East African Network for Monitoring Antimalarial Treatment
Muheza Designated District Hospital, Muheza, Tanga Region, Tanzania
Evelyn Ansah, district director of health services
Dangme West District Health Directorate/Research Centre, PO Box 1, Dodowa, Ghana
Karen I Barnes, associate professor
Division of Clinical Pharmacology, University of Cape Town, South Africa
Christopher JM Whitty, senior lecturer
Gates Malaria Partnership, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1B 3DP (c.whitty@lshtm.ac.uk)
Read all Rapid Responses